石药集团(01093.HK)附属出售石药中诺49.5%股权 代价3,465万人币
石药集团(01093.HK)公布,非全资附属公司石药中诺与石药控股订立股权转让协议,石药中诺将向後者出售石药中诚的49.5%股权,代价为3,465万元人民币(下同)。
完成後,公司将不再於石药中诚拥有任何权益。现时石药中诚结欠石药中诺及公司其他成员公司贷款合共5.57亿元,根据股权转让协议,石药控股亦将向石药中诚提供相关金额贷款以偿债。
集团预期因出售事项录得除税前收益约1,600万元。
石药控股为公司主要股东蔡东晨先生的联系人,因此,出售事项构成关连交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.